Population-based study of newly diagnosed multiple myeloma in Moscow: data from the Moscow City Cancer Registry (2022–2025)

E. N. Misyurina; Мисюрина Е. Н.; E. N. Zotina; Зотина Е. Н.; N. G. Chernova; Чернова Н. Г.; G. A. Dudina; Дудина Г. А.; T. N. Tolstykh; Толстых Т. Н.; N. A. Bodunova; Бодунова Н. А.; N. V. Oparina; Опарина Н. В.; A. V. Misyurin; Мисюрин А. В.; A. A. Solodovnik; Солодовник А. А.; A. S. Mkrtchyan; Мкртчян А. С.; E. A. Baryakh; Барях Е. А.; A. B. Makeshova; Макешова А. Б.; D. S. Maryin; Марьин Д. С.; V. N. Yakimets; Якимец В. Н.; D. S. Polyakov; Поляков Д. С.; R. S. Badaev; Бадаев Р. Ш.; O. A. Rukavitsyn; Рукавицын О. А.; P. A. Zeynalova; Зейналова П. А.; S. V. Semochkin; Семочкин С. В.; E. A. Mamaeva; Мамаева Е. А.; D. Y. Shibanova; Шибанова Д. Ю.; K. D. Kaplanov; Капланов К. Д.; I. S. Vlasov; Власов И. С.; T. A. Semina; Семина Т. А.; S. M. Gadzhieva; Гаджиева С. М.

doi:10.17650/1818-8346-2026-21-3-23-37

Population-based study of newly diagnosed multiple myeloma in Moscow: data from the Moscow City Cancer Registry (2022–2025)

Authors: Misyurina E.N.¹^,2, Zotina E.N.¹^,2, Chernova N.G.³, Dudina G.A.⁴, Tolstykh T.N.¹^,2, Bodunova N.A.⁴, Oparina N.V.⁴, Misyurin A.V.⁵, Solodovnik A.A.⁵^,6, Mkrtchyan A.S.⁶, Baryakh E.A.¹^,2^,7, Makeshova A.B.¹^,2, Maryin D.S.¹, Yakimets V.N.¹, Polyakov D.S.¹, Badaev R.S.¹^,2, Rukavitsyn O.A.²^,8, Zeynalova P.A.²^,9, Semochkin S.V.²^,10, Mamaeva E.A.³, Shibanova D.Y.⁴, Kaplanov K.D.¹¹, Vlasov I.S.¹², Semina T.A.¹², Gadzhieva S.M.¹²
Affiliations:
1. Moscow City Clinical Hospital No. 52, Moscow Healthcare Department
2. I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
3. Moscow Multidisciplinary Clinical Center "Kommunarka", Moscow Healthcare Department
4. Moscow Clinical Scientific and Practical Center named after A.S. Loginov, Moscow Healthcare Department
5. Vavilov Institute of General Genetics, Russian Academy of Sciences
6. GeneTechnology
7. Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
8. Main Military Clinical Hospital named after Acad. N.N. Burdenko, Ministry of Defense of Russia
9. Clinical Hospital "Lapino" of the "Mother and Child" Group of Companies
10. P.A. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Center, Ministry of Health of Russia
11. Botkin Hospital, Moscow Healthcare Department
12. Moscow Center for Monitoring and Development of Medical Care
Issue: Vol 21, No 3 (2026)
Pages: 23-37
Section: HEMATOLOGIC MALIGNANCIES: TREATMENT
Published: 30.09.2026
URL: https://oncohematology.abvpress.ru/ongm/article/view/1119
DOI: https://doi.org/10.17650/1818-8346-2026-21-3-23-37
ID: 1119

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription or Fee Access

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

Aim. To assess the registered incidence of multiple myeloma in Moscow, describe its age-, gender- and district-specific distribution, and provide a comprehensive clinical and biological characterization of adults with newly diagnosed multiple myeloma using the Moscow City Cancer Registry data for 2022–2025.

Materials and methods. This retrospective population-based registry study included 1,899 adults with newly diagnosed multiple myeloma recorded in the Moscow City Cancer Registry in 2022–2025. Crude and age-standardized incidence rates were calculated. For each administrative district, the annual number of new cases was normalized to the corresponding adult population size and presented as incidence per 100,000 persons. Temporal trends were assessed using regression models accounting for district and population size. The diagnostic interval and completeness of staging were also analyzed.

Results. The median age of patients was 68 [61; 74] years, and 55.1 % were women. Between 439 and 502 new cases were registered annually. No linear temporal trend was identified in the district-level analysis (p = 0.675). Mean annual crude district-specific rates ranged from 4.06 to 7.78 per 100,000 adults. The median diagnostic interval from the first outpatient visit to morphological verification was 19 [7; 54] days; the diagnosis was verified within ≤ 30 days in 61.2 % of cases. The proportion of patients assigned an mSMART 3.0 category increased from 36 % in 2022 to 70 % in 2025, while the availability of R2-ISS (Second Revision of the International Staging System) increased from 20 to 38 %.

Conclusion. This population-based study provides the first comprehensive description of contemporary epidemiological, clinical and biological features of newly diagnosed multiple myeloma in Moscow using the Moscow City Cancer Registry. Age standardization demonstrated a higher registered incidence in men despite the predominance of women in the cohort. The results obtained show increasing implementation of molecular-genetic risk stratification and support the registry as an instrument for population monitoring and improvement of specialized oncohematological care.

Keywords

multiple myeloma, epidemiology, Moscow City Cancer Registry, population-based study, incidence, age, cytogenetics, renal impairment

About the authors

E. N. Misyurina

Moscow City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Author for correspondence.
Email: misyurina_elena@mail.ru
ORCID iD: 0000-0003-2419-4850
Russian Federation, Build. 3, 3 Pekhotnaya St., Moscow, 123182; Build. 2, 8 Trubetskaya St., Moscow, 119048

E. N. Zotina

Moscow City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Email: misyurina_elena@mail.ru
ORCID iD: 0000-0001-9692-2541
Russian Federation, Build. 3, 3 Pekhotnaya St., Moscow, 123182; Build. 2, 8 Trubetskaya St., Moscow, 119048

N. G. Chernova

Moscow Multidisciplinary Clinical Center "Kommunarka", Moscow Healthcare Department

Email: misyurina_elena@mail.ru
ORCID iD: 0000-0002-0827-4052
Russian Federation, Build. 3, 8 Sosenskiy Stan St., Kommunarka, Moscow, 108814

G. A. Dudina

Moscow Clinical Scientific and Practical Center named after A.S. Loginov, Moscow Healthcare Department

Email: misyurina_elena@mail.ru
ORCID iD: 0000-0001-9673-1067
Russian Federation, Build. 1, 1 Novogireevskaya St., Moscow, 111123

T. N. Tolstykh

Moscow City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Email: misyurina_elena@mail.ru
ORCID iD: 0000-0001-7308-0927
Russian Federation, Build. 3, 3 Pekhotnaya St., Moscow, 123182; Build. 2, 8 Trubetskaya St., Moscow, 119048

N. A. Bodunova

Moscow Clinical Scientific and Practical Center named after A.S. Loginov, Moscow Healthcare Department

Email: misyurina_elena@mail.ru
ORCID iD: 0000-0002-3119-7673
Russian Federation, Build. 1, 1 Novogireevskaya St., Moscow, 111123

N. V. Oparina

Moscow Clinical Scientific and Practical Center named after A.S. Loginov, Moscow Healthcare Department

Email: misyurina_elena@mail.ru
ORCID iD: 0000-0001-8662-4794
Russian Federation, Build. 1, 1 Novogireevskaya St., Moscow, 111123

A. V. Misyurin

Vavilov Institute of General Genetics, Russian Academy of Sciences

Email: misyurina_elena@mail.ru
ORCID iD: 0000-0003-0558-8969
Russian Federation, 3 Gubkina St., Moscow, 119991

A. A. Solodovnik

Vavilov Institute of General Genetics, Russian Academy of Sciences; GeneTechnology

Email: misyurina_elena@mail.ru
ORCID iD: 0000-0001-8399-057X
Russian Federation, 3 Gubkina St., Moscow, 119991; 104 Profsoyuznaya St., Moscow, 117437

A. S. Mkrtchyan

GeneTechnology

Email: misyurina_elena@mail.ru
ORCID iD: 0000-0002-0638-213X
Russian Federation, 104 Profsoyuznaya St., Moscow, 117437

E. A. Baryakh

Moscow City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University); Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia

Email: misyurina_elena@mail.ru
ORCID iD: 0000-0001-6880-9269
Russian Federation, Build. 3, 3 Pekhotnaya St., Moscow, 123182; Build. 2, 8 Trubetskaya St., Moscow, 119048; Build. 1, 2/1 Barrikadnaya St., Moscow, 125993

References

International Agency for Research on Cancer. Global cancer observatory: cancer today. Multiple myeloma fact sheet. GLOBOCAN 2022. Lyon: IARC, 2024. Available at: https://gco.iarc.who.int/ (accessed 12.07.2026)
Mafra A., Laversanne M., Marcos-Gragera R. et al. The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045. J Natl Cancer Inst 2025;117(5):907–14. doi: 10.1093/jnci/djae321
Zhuge L., Lin X., Fan Z. et al. Global, regional and national epidemiological trends of multiple myeloma from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021. Front Public Health 2025;13:1527198. doi: 10.3389/fpubh.2025.1527198
Diao X., Ben T., Cheng S. et al. Global, regional, and national multiple myeloma burden from 1990 to 2021: a systematic analysis of the Global Burden of Disease Study 2021. BMC Public Health 2025;25(1):1054. doi: 10.1186/s12889-025-22240-2
National Cancer Institute. SEER cancer stat facts: myeloma. Available at: https://seer.cancer.gov/statfacts/html/mulmy.html (accessed 12.07.2026)
Wang S., Xu L., Feng J. et al. Prevalence and incidence of multiple myeloma in urban area in China: a national population-based analysis. Front Oncol 2020;9:1513. doi: 10.3389/fonc.2019.01513
Федеральная служба государственной статистики. Численность населения Российской Федерации по полу и возрасту на 1 января 2024 г: статистический бюллетень. М.: Росстат, 2024. Federal State Statistics Service. Population of the Russian Federation by sex and age as of January 1, 2024: statistical bulletin. Moscow: Rosstat, 2024. (In Russ.).
Управление Федеральной службы государственной статистики по г. Москве и Московской области (Мосстат). Москва в цифрах 2024: краткий статистический сборник. М.: Мосстат, 2025. Territorial Office of the Federal State Statistics Service for Moscow and the Moscow Region (Mosstat). Moscow in figures 2024: a brief statistical digest. Moscow: Mosstat, 2025. (In Russ.).
Управление Федеральной службы государственной статистики по г. Москве и Московской области (Мосстат). Оценка численности постоянного населения г. Москвы по состоянию на 1 января 2025 г. и в среднем за 2024 г. М.: Мосстат, 2025. Territorial Office of the Federal State Statistics Service for Moscow and the Moscow Region (Mosstat). Estimated permanent population of Moscow as of January 1, 2025, and annual average population for 2024. Moscow: Mosstat, 2025. (In Russ.).
Виноградова О.Ю., Птушкин В.В., Черников М.В. и др. Эпидемиология множественной миеломы в городе Москва. Терапевтический архив 2019;91(7):83–92. doi: 10.26442/00403660.2019.07.000305 Vinogradova O.Yu., Ptushkin V.V., Chernikov M.V. et al. Epidemiology of multiple myeloma in city Moscow. Terapevticheskiy arkhiv = Therapeutic Archive 2019;91(7):83–92. (In Russ.). doi: 10.26442/00403660.2019.07.000305
Департамент здравоохранения города Москвы. Приказ от 02.07.2020 № 677 «О ведении Московского городского канцер-регистра». Moscow Healthcare Department. Order No. 677 dated July 2, 2020, “On the Procedure for Maintaining the Moscow City Cancer Registry.” (In Russ.).
Dinmohamed A.G., Visser O., Verhoeven R.H.A. et al. Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands. Lancet Oncol 2020;21(6):750–1. doi: 10.1016/S1470-2045(20)30265-5
Von Elm E., Altman D.G., Egger M. et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Prev Med 2007;45(4):247–51. doi: 10.1016/j.ypmed.2007.08.012
Greipp P.R., San Miguel J., Durie B.G. et al. International Staging System for multiple myeloma. J Clin Oncol 2005;23(15):3412–20. doi: 10.1200/JCO.2005.04.242
Palumbo A., Avet-Loiseau H., Oliva S. et al. Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol 2015;33(26):2863–9. doi: 10.1200/JCO.2015.61.2267
D’Agostino M., Cairns D.A., Lahuerta J.J. et al. Second Revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma. J Clin Oncol 2022;40(29):3406–18. doi: 10.1200/JCO.21.02614
Rajkumar S.V. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol 2024;99(9):1802–24. doi: 10.1002/ajh.27422
Turesson I., Björkholm M., Blimark C.H. et al. Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival. Eur J Haematol 2018;101(2):237–44. doi: 10.1111/ejh.13083
Medhekar R., Ran T., Fu A.Z. et al. Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States. BMC Cancer 2022;22(1):901. doi: 10.1186/s12885-022-09980-9
Dimopoulos M.A., Sonneveld P., Leung N. et al. International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol 2016;34(13):1544–57. doi: 10.1200/JCO.2015.65.0044
Yadav P., Cook M., Cockwell P. Current trends of renal impairment in multiple myeloma. Kidney Dis (Basel) 2016;1(4):241–57. doi: 10.1159/000442511
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2024;105(4S):S117–314. doi: 10.1016/j.kint.2023.10.018
Мисюрина Е.Н., Зотина Е.Н., Гаджиева С.М. и др. Множественная миелома: ретроспективный анализ клинических исходов на основе регистра пациентов ГБУЗ «МКНИЦ Больница 52 ДЗМ» (2022–2025). Онкогематология 2025;20(4):41–50. doi: 10.17650/1818-8346-2025-20-4-41-50 Misyurina E.N., Zotina E.N., Gadzhieva S.M. et al. Multiple myeloma: a retrospective analysis of clinical outcomes based on the patient registry of the Moscow City Clinical Hospital No. 52 (2022–2025). Onkogematologiya = Oncohematology 2025;20(4):41–50. (In Russ.). doi: 10.17650/1818-8346-2025-20-4-41-50

Supplementary files

Supplementary Files

Action

1. JATS XML

Download

Username
Password
Remember me

Forgot password?	Register

Username
Password
Remember me

Forgot password?	Register